Genetic polymorphism contributes to 131I radiotherapy-induced toxicities in patients with differentiated thyroid cancer. (16th October 2018)

• Record Type: Journal Article
• Authors: Liu, Jianqiu; Tang, Xinyue; Shi, Feng; Li, Cuilin; Zhang, Ke; Liu, Jie; Wang, Guo; Yin, Jiye; Li, Zhi
• Is Part Of: Pharmacogenomics. Volume 19:Number 17(2018)
• Page Start: 1335
• Page End: 1344
• Publication Date: 2018-10-16
• Subjects: 131I radiotherapy -- SNPs -- toxicity reactions; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2018-0070
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: To investigate the association between SNPs in DNA damage response pathways and toxicities following 131 I radiotherapy of differentiated thyroid cancer (DTC).Materials & methods: We identified 22 functional SNPs of genes in DNA damage response pathways. MassArray was used to sequence SNP genotypes in 203 DTC patients. Hardy–Weinberg equilibrium and the associations between the two alleles of each SNP and toxicity reactions were evaluated using χ 2 analysis.Results: Ataxia-telangiectasia mutated ( ATM ) rs620815 T-allele carriers were at increased risk of 131 I radiation-induced gastrointestinal reaction compared with C allele carriers. TNFα rs1800629 GA genotype may increase the incidence of neck pain compared with GG genotype. Furthermore, TNFα rs1800629, ATM rs11212570, NF-κβ rs230493, and TGF-β rs1800469, rs2241716 were associated with throat pain following 131 I radiotherapy.Conclusion: The identified SNPs might serve as novel biomarkers for DTC treated with 131 I radiotherapy.